

Manisha Juthani, MD Commissioner



Ned Lamont Governor Susan Bysiewicz Lt. Governor

Immunization Program

TO: All Connecticut Vaccine Program (CVP) Providers

FROM: Mick Bolduc Mer Colle

Vaccine Coordinator, Connecticut Immunization Program

DATE: January 17, 2023

SUBJECT: Expansion of Human Papillomavirus Vaccine (HPV)

The purpose of this communication is to notify you of the expansion of the age eligibility of HPV vaccine available through the Connecticut Vaccine Program (CVP).

Age eligibility expansion will be incremental to stay within the current budget appropriation.

- Beginning April 1, 2023, HPV vaccine eligibility will be expanded to include all privately insured children aged 13 and 18 years;
- On July 1, 2023, privately insured children aged 14 and 17 years will become eligible;
- On July 1, 2024, privately insured children aged 15 and 16 years will become eligible. At this
 point in time, all children aged 11 through 18 will be eligible for HPV vaccines through the
 CVP.

As a reminder, children who initiate the HPV series at age 9 through 14 years only need 2 doses of vaccine, with a 6-month minimum interval separating doses. Children who initiate the HPV series at 15 years of age or older need 3 doses of vaccine. A link to the schedule can be found here.

A revised CVP eligibility criteria form is enclosed for your records.

As always if you have any questions, please feel free to contact me at (860) 509-7929.





Connecticut Vaccine Program (CVP) Eligibility Criteria as of April 1, 2023

| Vaccine | Age Group | Status of Children VFC and State Supplied Vaccine | | | | CPT |
|---------------------------|---------------------------------|---|----------------------|----------------------|---------------------|------------------------|
| | | | | | | Code(s) |
| | | | Non-VFC | Non-VFC | | , |
| | | VFC | Eligible | Eligible | a crims | |
| | | Eligible ¹ | Privately | Under- | S-CHIP ² | |
| | | | Insured ² | Insured ² | | |
| Hepatitis B | Newborns in hospital | YES | YES | YES | YES | 90744 |
| | Children 0-18 years | YES | YES | YES | YES | |
| Varicella (Doses 1 & 2) | 12 months-18 years ³ | YES | YES | YES | YES | 90716 |
| Td | 7-18 years ⁴ | YES | YES | YES | YES | 90714 |
| MMR | 12 months-18 years | YES | YES | YES | YES | 90707 |
| | College (any age) | YES | YES | YES | YES | |
| MMRV (Doses 1 & 2) | 12 months-12 years | YES | YES | YES | YES | 90710 |
| DTaP | 2 months – 6 years | YES | YES | YES | YES | 90700 |
| Hib | 2-59 months | YES | YES | YES | YES | 90647, 90648 |
| IPV | 2 months-18 years | YES | YES | YES | YES | 90713 |
| DTaP/IPV | 4-6 years | YES | YES | YES | YES | 90696 |
| DTaP/IPV/Hep B | 2-83 months | YES | YES | YES | YES | 90723 |
| DTaP/IPV/Hib | 2-59 months | YES | YES | YES | YES | 90698 |
| DTaP/IPV/Hib/Hep B | 2-59 months | YES | YES | YES | YES | 90697 |
| Meningococcal Conjugate | | | | | | |
| High Risk: | 2 months-10 years | YES | YES | YES | YES | 90619, |
| | | | | | | 90734 |
| Routine Doses 1 & 2: | 11-18 years | YES | YES | YES | YES | |
| Tdap | 7-18 years ⁵ | YES | YES | YES | YES | 90715 |
| Pneumococcal Conjugate 13 | 2 months-18 years | YES | YES | YES | YES | 90670 |
| Pneumococcal | 2-18 years | YES | YES | YES | YES | 90732 |
| Polysaccharide (PPSV23) | | | | | | 90732 |
| Influenza | 6 months-18 years | YES | YES | YES | YES | 90672, 90674, 90686 |
| Hepatitis A | 12 months -18 years | YES | YES | YES | YES | 90633 |
| Rotavirus | 6 weeks-8 months | YES | YES | YES | YES | 90680, 90681 |
| HPV (males & females) | 9,10, 14, 15, 16, 17 yrs | YES | NO | YES | YES | 90651 |
| | 11,12, 13 & 18 yrs | YES | YES | YES | YES | |
| Meningococcal Serogroup B | | | | | | |
| High Risk: | 10-18 years | YES | YES | YES | YES | 00/20 00/21 |
| | , | | | | | 90620, 90621 |
| Routine Doses 1 & 2: | 16-18 years | YES | YES | YES | YES | |
| Pneumococcal Conjugate 15 | - | YES | YES | YES | YES | 90671 |

^{1.} VFC eligibility is defined as follows: (a) Medicaid enrolled; (b) NO health insurance; (c) American Indian or Alaskan native; or (d) underinsured seen at an FOHC.

As of April 1, 2023, the only childhood vaccine not universally available from the CVP is HPV for privately insured patients 9-10, & 14-17 years of age. Providers can purchase this vaccine privately and submit billing requests to the appropriate insurer in accordance with normal billing procedures.

^{2.} Non-VFC children refers to patients who have private insurance that covers the cost of immunizations, patients that are under-insured for some or all vaccines seen by a private provider; and S-CHIP children- those children enrolled in HUSKY B.

^{3.} Susceptible children who do not have a clinical history of chicken pox.

^{4.} Td vaccine can be given to children 7-18 years of age to complete their primary series, or to those children 7-18 years of age who are in need of a Tetanus containing vaccine and cannot receive Tdap.

^{5.} Tdap vaccine should be administered routinely to children at the 11-12 year old preventive health care visit, and to children 7-10 & 13-18 years old who have not been fully vaccinated against pertussis and for whom no contraindication to pertussis containing vaccine exists.